Literature DB >> 8464478

Oncogene ect2 is related to regulators of small GTP-binding proteins.

T Miki1, C L Smith, J E Long, A Eva, T P Fleming.   

Abstract

We have developed an efficient expression cloning system that allows rapid isolation of complementary DNAs able to induce the transformed phenotype. We searched for molecules expressed in epithelial cells and possessing transforming potential to fibroblasts, and cloned a cDNA for the normal receptor of a growth factor secreted by NIH/3T3 cells. Here we report a second novel transforming gene, ect2. The isolated cDNA is activated by amino-terminal truncation of the normal product. The Ect2 protein has sequence similarity within a central core of 255 amino acids with the products of the breakpoint cluster gene, bcr (ref. 5), the yeast cell cycle gene, CDC24 (ref. 6), and the dbl oncogene. Each of these genes encodes regulatory molecules or effectors for Rho-like small GTP-binding proteins. The baculovirus-expressed Ect2 protein could bind highly specifically to Rho and Rac proteins, whereas the dbl product showed broader binding specificity to Rho family proteins. Thus ect2 is a new member of an expanding family, whose products have transforming properties and interact with Rho-like proteins of the Ras superfamily.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8464478     DOI: 10.1038/362462a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  90 in total

1.  Dependence of Dbl and Dbs transformation on MEK and NF-kappaB activation.

Authors:  I P Whitehead; Q T Lambert; J A Glaven; K Abe; K L Rossman; G M Mahon; J M Trzaskos; R Kay; S L Campbell; C J Der
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Nucleotide exchange factor ECT2 interacts with the polarity protein complex Par6/Par3/protein kinase Czeta (PKCzeta) and regulates PKCzeta activity.

Authors:  Xiu-Fen Liu; Hiroshi Ishida; Razi Raziuddin; Toru Miki
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

3.  Control of protein signaling using a computationally designed GTPase/GEF orthogonal pair.

Authors:  Gregory T Kapp; Sen Liu; Amelie Stein; Derek T Wong; Attila Reményi; Brian J Yeh; James S Fraser; Jack Taunton; Wendell A Lim; Tanja Kortemme
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-07       Impact factor: 11.205

Review 4.  Understanding cytokinesis failure.

Authors:  Guillaume Normand; Randall W King
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

5.  Protein kinase Cι promotes UBF1-ECT2 binding on ribosomal DNA to drive rRNA synthesis and transformed growth of non-small-cell lung cancer cells.

Authors:  Verline Justilien; Kayla C Lewis; Kayleah M Meneses; Lee Jamieson; Nicole R Murray; Alan P Fields
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

6.  Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation.

Authors:  Verline Justilien; Lee Jameison; Channing J Der; Kent L Rossman; Alan P Fields
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

7.  MgcRacGAP controls the assembly of the contractile ring and the initiation of cytokinesis.

Authors:  Wei-meng Zhao; Guowei Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

8.  Novel functions of Ect2 in polar lamellipodia formation and polarity maintenance during "contractile ring-independent" cytokinesis in adherent cells.

Authors:  Masamitsu Kanada; Akira Nagasaki; Taro Q P Uyeda
Journal:  Mol Biol Cell       Date:  2007-10-17       Impact factor: 4.138

9.  Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis.

Authors:  Pierre Morin; Cristina Flors; Michael F Olson
Journal:  Eur J Cell Biol       Date:  2009-06-09       Impact factor: 4.492

10.  Clinical significance of ECT2 expression in tissue and serum of gastric cancer patients.

Authors:  H-B Wang; H-C Yan; Y Liu
Journal:  Clin Transl Oncol       Date:  2015-10-26       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.